Question explored with the scientific record
Conversation so far
- 1 benefit of 1 mg melatonic/night for sleep
- 2 benefit of 1/2 mg klonopin for sleep
- 3 reasonably safe drug for chronic insomnia
- 4 what about 25 mg hydroxyzine for sleep in elderly
Answered on this page ↓
what about 25 mg hydroxyzine for sleep in elderly
The short version: 25 mg of hydroxyzine is a poor choice for an older adult's sleep, and the cardiac risk is the reason, not a footnote.
Hydroxyzine is a first-generation antihistamine, the same family as diphenhydramine (Benadryl). That class is sedating but also causes next-day hangover: impaired vigilance, divided attention, working memory, and slowed motor performance after a nighttime dose [3]. Drowsiness ratings do not track actual impairment, so feeling fine is not evidence of being fine [3]. In older adults, that daytime fog is a fall risk, and falls are the thing that actually breaks hips.
The specific worry with hydroxyzine is the heart. A case report describes a 34-year-old woman on 75 mg a day who developed repetitive fainting with a dangerously prolonged QT interval (a measure of how long the heart takes to reset between beats), which shortened after stopping the drug [4][5]. In the lab, hydroxyzine blocked the hERG potassium channel, the current that keeps that reset orderly, at low concentrations [4][5]. That patient carried a gene mutation; most people do not. But the mechanism is real, and older hearts have less reserve.
What this evidence does not contain: any trial of hydroxyzine for insomnia in the elderly, any trial at 25 mg, and any data on long-term nightly use. The retrieved records are a case report, a lab study, and a position statement on antihistamines generally [3][4][5]. The pediatric sedation study [2] and the bullying survey [1] are off-topic and I am not using them.
| Concern | What the evidence shows |
|---|---|
| Next-day impairment | Impaired attention, memory, motor speed [3] |
| Drowsiness as a guide | Ratings did not predict impairment [3] |
| Cardiac | QT prolongation, syncope in one case [4][5] |
| hERG channel block | Potent block at low concentration [4][5] |
| Insomnia trial in elderly | None in this evidence |
My call: for an older adult with chronic insomnia, I would not start 25 mg hydroxyzine; the sedation is real but so is the next-day impairment and the QT signal, and no trial here shows it helps this population. Confidence: moderate on the harm mechanism, low on any benefit, because the efficacy evidence for this exact use is absent.
Sources used 5
-
Acute Emergence of Suicidal Thoughts Following Lemborexant Initiation: An Adverse Reaction Case Report
A survey of 101 psychiatric clinic patients found high rates of bullying (80% lifetime, 49% past-year), with emotional/verbal most common, and many reports leading to no action despite zero-tolerance policies.
DOI: 10.1017/s1092852923002134 -
Oral Sedation Postdischarge Adverse Events in Pediatric Dental Patients
In a prospective single-center cohort of 46 pediatric dental sedation visits, postdischarge excessive somnolence was common, nausea and vomiting were also reported, and recovery sometimes took more than 10 hours.
DOI: 10.2344/0003-3006-62.3.91 -
CSACI position statement: Newer generation H1-antihistamines are safer than first-generation H1-antihistamines and should be the first-line antihistamines for the treatment of allergic rhinitis and urticaria
This CSACI position statement concludes that newer generation H1-antihistamines are safer, faster-acting and more efficacious than first-generation agents, and should be first-line therapy for allergic rhinitis and urticaria.
DOI: 10.1186/s13223-019-0375-9 -
Hydroxyzine, a First Generation H1-Receptor Antagonist, Inhibits Human Ether-a-go-go–Related Gene (HERG) Current and Causes Syncope in a Patient With the HERG Mutation
This paper reports a case of hydroxyzine-induced QT prolongation and syncope in a patient harboring a heterozygous A614V HERG mutation, and provides in vitro evidence that hydroxyzine inhibits WT and WT/A614V HERG currents (with A614V being trafficking-deficient), illustrating a…
DOI: 10.1254/jphs.08178FP -
Hydroxyzine, a First Generation H1-Receptor Antagonist, Inhibits Human Ether-a-go-go–Related Gene (HERG) Current and Causes Syncope in a Patient With the HERG Mutation
This study reports a case of drug-induced long QT syndrome associated with the H1-receptor antagonist hydroxyzine in a patient with a HERG gene mutation, demonstrating the drug's potential to inhibit HERG currents and cause severe cardiac events.
DOI: 10.1254/jphs.08178fp